Demineralized Bone Fiber (DBF™) patent to expand TheraCell’s osteobiologic patent portfolio
Northridge, Cali. and Centennial, Colo. — March 9, 2017 — TheraCell, a regenerative medicine company, today announced it was awarded a second patent for its demineralized bone fiber (DBF™) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,572,912, titled Demineralized bone fibers having controlled geometry and shapes and methods thereof, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry.
TheraCell’s DBF™ technology is incorporated into two innovative demineralized cortical fiber allografts, AlloFuse® Cortical Fibers and AlloFuse® Fiber Boat, commercialized by AlloSource, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures to advance patient healing.
“The TheraCell demineralized bone fiber is an exciting new biomaterial that appears to perform very well in the pre-clinical studies that I have done. The fibers have a nano topography that is cell friendly, based on in vitro and in vivo experiments that coupled with the fiber geometry and lack of excipients makes an easily handled high performance bone graft material,” said Professor Bill Walsh, UNSW Australia.
AlloSource’s AlloFuse Cortical Fibers and AlloFuse Fiber Boat may be appropriate to fill bone voids or cages in spinal and orthopedic procedures. Both AlloFuse Fiber products contain demineralized cortical bone and are designed for fluid absorbency.
“This second patent shows TheraCell’s dedication to advancing the science behind demineralized bone fiber allografts,” said Kerr Holbrook, AlloSource Chief Commercial Officer. “Including this patented technology in AlloSource’s product portfolio is important to providing our surgeon customers solutions to help patients in need, while continuing to fully honor our tissue donors.”